Innate Pharma (Nasdaq: IPHA) details April 2026 share and voting rights
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Innate Pharma S.A. reports its capital and voting structure as of April 16, 2026. The company has 93,934,210 shares outstanding, made up of 93,921,863 ordinary shares, 4,766 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical voting rights is 93,921,863, while exercisable voting rights, excluding treasury shares with suspended rights, total 93,903,288.
Positive
- None.
Negative
- None.
Key Figures
Shares outstanding: 93,934,210 shares
Ordinary shares: 93,921,863 shares
Preferred Shares 2016: 4,766 shares
+3 more
6 metrics
Shares outstanding
93,934,210 shares
Total shares outstanding as of April 16, 2026
Ordinary shares
93,921,863 shares
Ordinary shares included in total share count
Preferred Shares 2016
4,766 shares
Preferred Shares 2016 within total capital
Preferred Shares 2017
7,581 shares
Preferred Shares 2017 within total capital
Theoretical voting rights
93,921,863 rights
Gross voting rights for threshold calculations
Exercisable voting rights
93,903,288 rights
Net voting rights excluding treasury shares
Key Terms
theoretical voting rights, exercisable voting rights, Preferred Shares 2016, Preferred Shares 2017, +2 more
6 terms
theoretical voting rights financial
"Total number of theoretical voting rights (1): 93,921,863"
Theoretical voting rights are the share of control an investor would have if all possible sources of additional shares—such as stock options, warrants and convertible bonds—were turned into ordinary shares. Investors care because this “what-if” number shows potential dilution of current owners and the maximum voting power others could gain, helping assess control risk and how future actions might change company decisions, like a snapshot of ownership if every coupon were cashed in.
exercisable voting rights financial
"Total number of exercisable voting rights (2): 93,903,288"
Exercisable voting rights are the actual, usable votes attached to a security or position that allow the holder to influence company decisions at shareholder meetings—for example electing the board or approving mergers. They matter to investors because the number of votes someone can cast determines who controls the company and its strategy, similar to having usable tickets at a town meeting rather than placeholders, and can affect share value, takeover risk and how much influence minority holders have.
Universal Registration Document regulatory
"Risk Factors section of the Universal Registration Document filed with the French Financial Markets Authority"
A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.
Autorité des Marchés Financiers regulatory
"article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation"
Autorité des marchés financiers is the French-language name for an independent government agency that supervises and enforces rules for securities markets, financial firms, and investor protection. It matters to investors because it requires companies to publish accurate information, polices fraud and insider trading, and can suspend trading or impose penalties—acting like a referee and safety inspector to help markets stay fair and reliable and to give investors confidence and recourse.
FAQ
How many voting rights does Innate Pharma (IPHA) have outstanding?
Innate Pharma reported 93,921,863 theoretical voting rights and 93,903,288 exercisable voting rights. Theoretical rights include all shares with attached votes, while exercisable rights exclude treasury shares whose voting rights are suspended under French market regulations.
On which stock exchanges is Innate Pharma (IPHA) listed?
Innate Pharma is listed on Euronext Paris under the ticker IPH and on Nasdaq under the ticker IPHA. These dual listings give the biotechnology company access to both European and U.S. equity markets and investor bases.
What kind of company is Innate Pharma (IPHA) and what does it develop?
Innate Pharma is a global, clinical-stage biotechnology company focused on immunotherapies for cancer. It develops next-generation antibody-based therapeutics, including programs like IPH4502, lacutamab and monalizumab, often in collaboration with partners such as AstraZeneca and Sanofi.
Why does Innate Pharma publish theoretical and exercisable voting rights?
Innate Pharma publishes both theoretical and exercisable voting rights to comply with French AMF regulations. Theoretical rights are used for threshold calculations, while exercisable rights, adjusted for treasury shares, aim to keep the market properly informed about actual voting power.